

Palladium-Catalyzed Conversion of Aryl and Vinyl Triflates to Bromides and Chlorides

*Xiaoqiang Shen, Alan M. Hyde, and Stephen L. Buchwald**

Department of Chemistry, Room 18-490
Massachusetts Institute of Technology
Cambridge, MA 02139 (USA)
FAX: (+1) 617-253-3297
E-mail: sbuchwal@mit.edu

Supporting Information


GENERAL CONSIDERATIONS

Reagents. Unless otherwise stated, all reactions were carried out in resealable screw-cap tubes under an argon atmosphere using standard Schlenk techniques or glovebox for the manipulation of solvents and reagents. Toluene was purchased from J.T. Baker in a CYCLE-TAINER solvent-deliver keg and vigorously purged with argon for 2 hours. The solvent was further purified by passing through successive alumina and Q5 reactant-packed columns on a solvent purification system. $\text{Pd}_2(\text{dba})_3$ was purchased from Strem. PEG 3400 [poly(ethylene glycol), $M_n = \sim 3400$], Me_2PEG 2000 [poly(ethylene glycol) dimethyl ether, $M_n = \sim 2000$], and *i*- Bu_3Al solution (1.0 M in toluene, 25 wt.%, Sure/SealTM) were purchased from Aldrich, KBr (powdered, IR quality) was purchased from Harshaw, KCl was purchased from J.T. Baker Chemical Co., 2-butanone was purchased from Alfa Aesar, and all these chemicals were used as received. *i*- $\text{Pr}_3\text{Al}\cdot\text{OEt}_2$ was prepared by the method of Lehmkuhl¹ and *t*-BuBrettPhos was prepared as reported by Fors.² Flash chromatography was performed with EM Science silica gel 60 (230-400 mesh) or using a Biotage SP4 instrument with prepacked silica cartridges (25 g).

Analytical Methods. All new compounds were characterized by ^1H NMR, ^{13}C NMR, ^{19}F NMR (where applicable), IR spectroscopy and in most cases, elemental analysis. ^1H NMR and ^{13}C NMR spectra are included for all compounds. ^1H and ^{13}C NMR spectra were recorded on a Varian 300 MHz or Bruker 400 MHz. Infrared spectra were recorded on a Perkin-Elmer Model 2000 FT-IR using NaCl plates (thin film). Elemental analyses were performed by Atlantic Microlab Inc., Norcross, GA. All ^1H NMR spectra are reported in parts per million (ppm) downfield of TMS and were measured relative to the signals for CHCl_3 (7.27 ppm). All ^{13}C NMR spectra were reported in ppm relative to residual CHCl_3 (77 ppm) and were obtained with ^1H decoupling. Melting points were obtained on a Mel-Temp capillary melting point apparatus. Gas chromatographic analyses were performed on Hewlett-Packard 6890 gas chromatography instrument with a FID detector using 25m x 0.20 mm capillary column with cross-linked methyl siloxane as the stationary phase. The yields reported in tables 2 and 3 refer to isolated yields and represent an average of at least two independent runs. The pure compounds are estimated to be $\geq 95\%$ pure as determined by ^1H NMR and GC analysis and/or combustion analysis.


Analytical Data for Trifluoromethanesulfonates:

4-methoxyphenyl trifluoromethanesulfonate and 6-quinoliny trifluoromethanesulfonate were purchased from Aldrich. (*R*)-2,8-dimethyl-2-((4*R*,8*R*)-4,8,12-trimethyltridecyl)-chroman-6-yl trifluoromethanesulfonate,³ (8*R*,9*S*,13*S*,14*S*)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6*H*-cyclopenta[*a*]phenanthren-17-yl trifluoromethanesulfonate,⁴ (8*R*,9*S*,13*S*,14*S*)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolan]-3-yl trifluoromethanesulfonate,⁵ (8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl trifluoromethanesulfonate,⁶ *tert*-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-9*H*-carbazole-9-carboxylate,⁷ *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate,⁷ 1,2,3,6-tetrahydro-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate,⁸ 3-bromophenyl trifluoromethanesulfonate,⁹ and ethyl 4-(((trifluoromethyl)sulfonyl)oxy)benzoate,¹⁰ were prepared according to literature procedures.



***tert*-butyl-5-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate:**


White solid, MP = 44.5-46.5 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.22 (d, *J* = 9.0 Hz, 1H), 7.70 (d, *J* = 3.6 Hz, 1H), 7.47 (d, *J* = 2.4 Hz, 1H), 7.21 (dd, *J* = 9.0, 2.4 Hz, 1H), 6.59 (dd, *J* = 3.9, 0.9 Hz, 1H), 1.68 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 149.2, 145.2, 134.1, 131.2, 128.2, 118.8 (q, *J* = 319 Hz), 117.0, 116.3, 113.4, 107.0, 84.5, 28.0; ¹⁹F NMR (282 MHz, CDCl₃) δ -73.2. IR (thin film): 1742, 1464, 1423, 1208 cm⁻¹. Elemental analysis for C₁₄H₁₄F₃NO₅S: C, 46.03; H, 3.86. Found: C, 46.17; H, 3.78.



***tert*-butyl-6-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate:**

Colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 7.70 (d, *J* = 3.6 Hz, 1H), 7.59 (d, *J* = 8.7 Hz, 1H), 7.16 (dd, *J* = 8.7, 2.4 Hz, 1H), 6.61 (d, *J* = 3.9 Hz, 1H), 1.70 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 149.1, 146.6, 134.7, 130.1, 128.0, 121.7, 118.8 (q, *J* = 319 Hz), 116.0, 108.8, 106.8, 84.7, 28.0; ¹⁹F NMR (282 MHz, CDCl₃) δ -73.2. IR (thin film): 1743, 1446, 1423, 1347, 1210 cm⁻¹; Elemental analysis for C₁₄H₁₄F₃NO₅S: C, 46.03; H, 3.86. Found: C, 46.28; H, 3.92.


General Procedure for the Bromination or Chlorination of Aryl Triflates: A screw-cap test tube (VWR catalog # 53283-810) or a Kontes Schlenk tube (with HI-VAC valve) equipped with a magnetic stir bar was charged with the Pd₂(dba)₃ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), KBr or KCl (1.5 mmol), PEG3400 (120mg) and aryl triflate (1.0 mmol, 1.0 equiv). The tube was sealed off with a screw-cap, evacuated and backfilled with argon, this procedure was done two more times, 2-butanone (1.5 mmol) and toluene (6-8 mL; Note: the reaction concentration is about 0.1-0.13 M, at higher concentrations (0.2 M), PEG3400 sometime gives gelling and this can be prevented by using Me₂PEG 2000 as phase transfer catalyst) were injected into the tube sequentially, the mixture was stirred for 1 min, then 1.5 mL of *i*-Bu₃Al (1M solution in toluene, 1.5 mmol) was added dropwise. The resulting mixture was stirred vigorously at 100 °C for 20–24 h. The reaction mixture was then cooled to room temperature, diluted with diethyl ether (~10 mL), and then filtered through a pad of silica gel (eluted with ether) and concentrated under reduced pressure. The crude material was purified by flash chromatography on silica gel.




1-bromo-4-butylbenzene (CAS No. 41492-05-1):

The title compound was prepared according to the general procedure with 4-*n*-butylphenyl trifluoromethanesulfonate (282 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a colorless oil (175 mg, 82%). ¹H NMR (300 MHz, CDCl₃) δ 7.40 (d, *J* =


8.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 2.58 (t, J = 7.8 Hz, 2H), 1.64-1.54 (m, 2H), 1.42-1.29 (m, 2H), 0.94 (t, J = 7.5 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 141.8, 131.2, 130.1, 119.2, 35.0, 33.5, 22.2, 13.9.




1-bromo-4-methoxybenzene (CAS No. 104-92-7): The title compound was prepared according to the general procedure with 4-methoxyphenyl trifluoromethanesulfonate (256 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (Biotage, eluted with 0-5% EtOAc in hexanes) to provide the desired product as a colorless oil (131 mg, 70%). ^1H NMR (300 MHz, CDCl_3) δ 7.35 (d, J = 9.0 Hz, 1H), 6.75 (d, J = 9.0 Hz, 2H), 3.75 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 158.6, 132.2, 115.7, 112.8, 55.4.




1-bromo-2,4-dimethylbenzene (CAS No. 583-70-0): The title compound was prepared according to the general procedure with 2,4-dimethylphenyl trifluoromethanesulfonate (254 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (18.3mg, 2.0 mol%), *t*-BuBrettPhos (24.2 mg, 5.0 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (8 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a colorless oil (122 mg, 66%). ^1H NMR (300 MHz, CDCl_3) δ 7.42 (d, J = 8.1 Hz, 1H), 7.08 (s, 1H), 6.88 (d, J = 8.1 Hz, 1H), 2.39 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 137.4, 137.0, 132.0, 131.6, 128.1, 121.5, 22.8, 20.8.



7-bromo-1-naphthylamine:¹¹ The title compound was prepared according to the general procedure with 8-amino-2-naphthyl trifluoromethanesulfonate (291 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (18.3mg, 2.0 mol%), *t*-BuBrettPhos (24.2 mg, 5.0 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-15% EtOAc in hexanes) to provide the desired product as a white solid (144 mg, 65%), turned darker upon standing. ^1H NMR (300 MHz, CDCl_3) δ 8.0 (s, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.53 (dd, J = 8.7, 1.8 Hz, 1H), 7.34-7.27 (m, 2H), 6.79 (dd, J = 6.3, 2.1 Hz, 1H), 4.09 (br, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 141.2, 132.7, 130.2, 129.1, 126.8, 124.8, 123.5, 118.8, 118.7, 110.7.




1,3-dibromobenzene (CAS No. 108-36-1): The title compound was prepared according to the general procedure with 3-bromophenyl trifluoromethanesulfonate (305 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a colorless oil (184 mg, 78%). ^1H NMR (300 MHz, CDCl_3) δ 7.69 (t, J = 1.8 Hz, 1H), 7.44 (dd, J = 7.8, 1.8 Hz, 2H), 7.12 (t, J = 7.8 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 134.2, 131.1, 130.2, 123.0.




1-bromo-4-chloronaphthalene:¹² The title compound was prepared according to the general procedure with 4-chloro-1-naphthyl trifluoromethanesulfonate (311 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a white solid (217 mg, 90%), which contains inseparable 1,4-dichloronaphthalene and 1,4-dibromonaphthalene (4-10% total). ^1H NMR (300 MHz, CDCl_3) δ


8.29-8.21 (m, 2H), 7.68-7.62 (m, 3H), 7.40 (d, J = 4.1 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 132.6, 131.7, 131.6, 129.5, 128.0, 127.7, 127.6, 126.3, 124.9, 121.5.




5-bromo-2-methylbenzo[d]thiazole (CAS No. 63837-11-6): The title compound was prepared according to the general procedure with 2-methylbenzo[d]thiazol-5-yl trifluoromethanesulfonate (297 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (18.3mg, 2.0 mol%), *t*-BuBrettPhos (24.2 mg, 5.0 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-15% EtOAc in hexanes) to provide the desired product as a white solid (171 mg, 75%). ^1H NMR (300 MHz, CDCl_3) δ 8.08 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.44 (dd, J = 8.5, 1.9 Hz, 1H), 2.83 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 168.6, 154.4, 134.3, 127.6, 125.1, 122.3, 119.3, 20.1.




5-chloro-2-methylbenzo[d]thiazole (CAS No. 1006-99-1): The title compound was prepared according to the general procedure with 2-methylbenzo[d]thiazol-5-yl trifluoromethanesulfonate (297 mg, 1 mmol), potassium chloride (112 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (18.3mg, 2.0 mol%), *t*-BuBrettPhos (24.2 mg, 5.0 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-20% EtOAc in hexanes) to provide the desired product as a white solid (154mg, 84%). ^1H NMR (300 MHz, CDCl_3) δ 7.88 (d, J = 1.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.26 (dd, J = 8.4, 1.9 Hz, 1H), 2.78 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 168.8, 154.1, 133.8, 131.8, 125.0, 122.1, 121.9, 20.1.



6-bromoquinoline (CAS No. 5332-25-2): The title compound was prepared according to the general procedure with 6-quinolinyl trifluoromethanesulfonate (227 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-30% EtOAc in hexanes) to provide the desired product as a colorless oil (131 mg, 63%). ^1H NMR (300 MHz, CDCl_3) δ 8.90 (dd, J = 4.2, 1.8 Hz, 1H), 8.05-8.01 (m, 1H), 7.96 (d, J = 6.0 Hz, 1H), 7.94 (s, 1H), 7.75 (dd, J = 9.0, 2.1 Hz, 1H), 7.39 (dd, J = 8.1, 4.2 Hz, 1H), ^{13}C NMR (75 MHz, CDCl_3) δ 150.7, 146.7, 135.0, 132.8, 131.1, 129.7, 129.2, 121.8, 120.4.




4-bromo-1,2,3,6-tetrahydro-1,1'-biphenyl: The title compound was prepared according to the general procedure with 1,2,3,6-tetrahydro-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate (306 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as an off-white solid (206 mg, 87%). MP = 44-45.5 °C. ^1H NMR (300 MHz, CDCl_3) δ 7.38-7.23 (m, 5H), 6.15 (br, 1H), 2.93-2.83 (m, 1H), 2.73-2.53 (m, 2H), 2.42-2.22 (m, 2H), 2.03-1.91 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.5, 128.5, 128.4, 126.7, 126.3, 121.9, 38.7, 35.5, 35.2, 31.4. IR (thin film): 2923, 1492, 1452, 1433, 961 cm^{-1} ; Elemental analysis for $\text{C}_{12}\text{H}_{13}\text{Br}$: C, 60.78; H, 5.53. Found: C, 61.23; H, 5.59.




tert-butyl 2-bromo-9H-carbazole-9-carboxylate: The title compound was prepared according to the general procedure with *tert*-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-9H-carbazole-9-carboxylate (415 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), $\text{Pd}_2(\text{dba})_3$ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol),


2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (8 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-10% EtOAc in hexanes) to provide the desired product as a white solid (251 mg, 73%). MP = 126-127.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1H), 8.28 (d, J = 8.4 Hz, 1H), 7.94-7.92 (m, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.52-7.46(m, 2H), 7.37 (t, J = 7.7 Hz, 1H), 1.79 (s, 9H), ¹³C NMR (100 MHz, CDCl₃) δ 150.7, 139.1, 138.4, 127.4, 126.1, 124.9, 124.6, 123.2, 120.6, 120.5, 119.54, 119.52, 116.3, 84.5, 28.3. IR (thin film): 1729, 1418, 1331, 1155 cm⁻¹; Elemental analysis for C₁₇H₁₆BrNO₂: C, 58.97; H, 4.66. Found: C, 59.20; H, 4.84.




tert-butyl-6-bromo-1H-indole-1-carboxylate (CAS No. 147621-26-9): The title compound was prepared according to the general procedure with *tert*-butyl 6-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate (365 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-2% EtOAc in hexanes) to provide the desired product as a white solid (225 mg, 76%). ¹H NMR (300 MHz, CDCl₃) δ 8.28 (s, 1H), 7.48 (d, J = 3.9 Hz, 1H), 7.33 (dd, J = 8.4, 0.3 Hz, 1H), 7.26 (dd, J = 8.1, 1.5 Hz, 1H), 6.45 (dd, J = 3.9, 0.9 Hz, 1H), 1.60 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 149.3, 135.8, 129.3, 126.3, 125.8, 121.9, 118.3, 117.9, 107.0, 84.2, 28.1.



tert-butyl-4-bromo-1H-indole-1-carboxylate (CAS No. 676448-17-2): The title compound was prepared according to the general procedure with *tert*-butyl 4-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate (365 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-2% EtOAc in hexanes) to provide the desired product as a white solid (222 mg, 75%). ¹H NMR (300 MHz, CDCl₃) δ 8.12 (d, J = 8.2 Hz, 1H), 7.65 (d, J = 3.7 Hz, 1H), 7.40 (dd, J = 7.8, 0.7 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 6.65 (dd, J = 3.8, 0.7 Hz, 1H), 1.69 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 149.4, 135.5, 131.1, 126.4, 125.5, 125.1, 114.6, 114.2, 107.0, 84.2, 28.1.




tert-butyl-5-bromo-1H-indole-1-carboxylate (CAS No. 182344-70-3): The title compound was prepared according to the general procedure with *tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-1*H*-indole-1-carboxylate (365 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-2% EtOAc in hexanes) to provide the desired product as a white solid (207 mg, 70%). ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d, J = 8.7 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.41 (dd, J = 8.7, 1.8 Hz, 1H), 6.51 (d, J = 3.9 Hz, 1H), 1.68 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 149.4, 133.9, 132.2, 127.0, 123.5, 116.5, 115.9, 106.4, 84.1, 28.1.




Ethyl-4-bromobenzoate (CAS No. 5798-75-4): The title compound was prepared according to the general procedure with ethyl 4-(((trifluoromethyl)sulfonyl)oxy)benzoate (298 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.25 mL, 1.25 mmol), EtOH (58 mg, 1.25 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (Biotage, eluted with 0-8% EtOAc in hexanes) to provide the desired product as a colorless oil (183 mg, 80%) which contains about 5% of inseparable ethyl 4-*i*-butylbenzoate. ¹H NMR (300


MHz, CDCl₃) δ 7.90 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 4.37 (q, J = 7.2 Hz, 2H), 1.39 (t, J = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.8, 131.6, 131.0, 129.3, 127.8, 61.2, 14.2.




Ethyl-4-chlorobenzoate (CAS No. 7335-27-5): The title compound was prepared according to the general procedure with ethyl 4-(((trifluoromethyl)sulfonyl)oxy)benzoate (298 mg, 1 mmol), potassium chloride (112 mg, 1.5 mmol), Pd₂(dba)₃ (13.7mg, 1.5 mol%), *t*-BuBrettPhos (18.2 mg, 3.75 mol%), *i*-Bu₃Al (1.25 mL, 1.25 mmol), EtOH (58 mg, 1.25 mmol) and PEG3400 (120 mg) in toluene (6 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (Biotage, eluted with 0-10% EtOAc in hexanes) to provide the desired product as a colorless oil (155 mg, 84%) which contains about 5% of inseparable ethyl 4-*i*-butylbenzoate. ¹H NMR (300 MHz, CDCl₃) δ 7.96 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 4.35 (q, J = 7.2 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.6, 139.1, 130.8, 128.8, 128.5, 61.1, 14.2.



(R)-6-bromo-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman: The title compound was prepared according to the general procedure with (*R*)-2,8-dimethyl-2-((4*R*,8*R*)-4,8,12-trimethyltridecyl)chroman-6-yl trifluoromethanesulfonate (535 mg, 1 mmol), potassium bromide (179 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (8 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a colorless oil (335 mg, 72%). ¹H NMR (300 MHz, CDCl₃) δ 7.09 (s, 1H), 7.04 (s, 1H), 2.73 (t, J = 6.6 Hz, 2H), 2.15 (s, 3H), 1.85-1.72 (m, 3H), 1.63-1.07 (m, 20H), 1.27 (s, 3H), 0.91-0.86 (m, 12H); ¹³C NMR (75 MHz, CDCl₃) δ 151.2, 130.8, 129.2, 128.6, 122.5, 110.7, 76.3, 39.9, 39.3, 37.42, 37.37, 37.36, 37.26, 32.8, 32.6, 30.9, 28.0, 24.8, 24.4, 24.1, 22.7, 22.6, 22.2, 20.9, 19.7, 19.6, 15.9. IR (thin film): 2927, 1468, 1219 cm⁻¹.




(R)-6-chloro-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman: The title compound was prepared according to the general procedure with (*R*)-2,8-dimethyl-2-((4*R*,8*R*)-4,8,12-trimethyltridecyl)chroman-6-yl trifluoromethanesulfonate (535 mg, 1 mmol), potassium chloride (112 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (8 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (eluted with hexanes) to provide the desired product as a colorless oil (307 mg, 73%). ¹H NMR (400 MHz, CDCl₃) δ 6.95 (s, 1H), 6.91 (s, 1H), 2.76-2.73 (m, 2H), 2.17 (s, 3H), 1.86-1.73 (m, 2H), 1.60-1.09 (m, 24H), 0.92-0.86 (m, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 150.6, 128.04, 127.97, 126.2, 123.3, 121.9, 76.2, 39.9, 39.4, 37.44, 37.38, 37.28, 32.8, 32.6, 31.0, 28.0, 24.8, 24.5, 24.1, 22.7, 22.6, 22.2, 20.9, 19.8, 19.7, 15.9. IR (thin film): 2927, 1469, 1220 cm⁻¹. Elemental analysis for C₂₇H₄₅ClO: C, 77.01; H, 10.77. Found: C, 77.04; H, 10.73.




(8R,9S,13S,14S)-17-bromo-3-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene: The title compound was prepared according to the general procedure with (8*R*,9*S*,13*S*,14*S*)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6*H*-cyclopenta[a]phenanthren-17-yl

trifluoromethanesulfonate (208 mg, 0.5 mmol), potassium bromide (90 mg, 0.75 mmol), Pd₂(dba)₃ (11.5mg, 2.5 mol%), *t*-BuBrettPhos (15.2 mg, 6.25 mol%), *i*-Bu₃Al (0.75 mL, 0.75 mmol), 2-butanone (54 mg, 0.75 mmol) and PEG3400 (60 mg) in toluene (4 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-10% EtOAc in hexanes) to provide the desired product as a white solid (160 mg, 92%). ¹H NMR (400 MHz, CDCl₃) δ 7.22 (d, J = 8.6 Hz, 1H), 6.74 (dd, J = 8.6, 2.8 Hz, 1H), 6.67 (d, J = 2.8 Hz, 1H), 5.90 (dd, J = 3.2, 1.6 Hz, 1H), 3.80 (s, 3H), 2.94-2.90 (m, 2H), 2.45-2.39 (m, 1H), 2.33-2.26 (m, 1H), 2.26 (ddd, J = 14.8, 6.3, 3.3 Hz, 1H), 2.03 (ddd, 14.7, 11.1, 1.7 Hz, 1H), 1.98-1.87 (m, 2H), 1.75 (td, 11.2, 6.3 Hz, 1H), 1.67-1.40 (m, 4H), 0.89 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.4, 137.7, 135.7, 132.4, 128.9, 125.9, 113.8, 111.3, 55.1, 54.7, 48.8, 44.1, 37.4, 34.5, 31.5, 29.5, 27.2, 26.2, 15.2. IR (thin film): 2931, 1609, 1499, 1256 cm⁻¹. Elemental analysis for C₁₉H₂₃BrO: C, 65.71; H, 6.68. Found: C, 65.94; H, 6.73.




(8*R*,9*S*,13*S*,14*S*)-17-chloro-3-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6*H*-cyclopenta[*a*]phenanthrene:

¹³ The title compound was prepared according to the general procedure with (8*R*,9*S*,13*S*,14*S*)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15-octahydro-6*H*-cyclopenta[*a*]phenanthren-17-yl trifluoromethanesulfonate (208 mg, 0.5 mmol), potassium chloride (56 mg, 0.75 mmol), Pd₂(dba)₃ (11.5mg, 2.5 mol%), *t*-BuBrettPhos (15.2 mg, 6.25 mol%), *i*-Bu₃Al (0.75 mL, 0.75 mmol), 2-butanone (54 mg, 0.75 mmol) and PEG3400 (60 mg) in toluene (4 mL) at 100 °C for 24h. The crude product was purified by flash chromatography (Biotage, eluted with 0-10% EtOAc in hexanes) to provide the desired product as a white solid (142 mg, 94%). ¹H NMR (300 MHz, CDCl₃) δ 7.25 (d, J = 8.7 Hz, 1H), 6.77 (dd, J = 8.7, 2.7 Hz, 1H), 6.70 (d, J = 2.7 Hz, 1H), 5.70 (dd, J = 3.0, 1.6 Hz, 1H), 3.83 (s, 3H), 2.96-2.92 (m, 2H), 2.48-2.41 (m, 1H), 2.37-2.25 (m, 2H), 2.08 (ddd, J = 14.4, 10.8, 1.5 Hz, 1H), 2.01-1.93 (m, 2H), 1.81-1.68 (m, 1H), 1.68-1.41 (m, 4H), 0.95 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 157.4, 144.7, 137.7, 132.5, 126.0, 124.5, 113.8, 111.4, 55.1, 54.9, 47.8, 44.2, 37.3, 33.7, 30.3, 29.6, 27.2, 26.2, 15.1.



(8*R*,9*S*,13*S*,14*S*)-3-bromo-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolane]:


The title compound was prepared according to the general procedure with (8*R*,9*S*,13*S*,14*S*)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolan]-3-yl trifluoromethanesulfonate (223 mg, 0.5 mmol), potassium bromide (90 mg, 0.75 mmol), Pd₂(dba)₃ (11.5mg, 2.5 mol%), *t*-BuBrettPhos (15.2 mg, 6.25 mol%), *i*-Bu₃Al (0.75 mL, 0.75 mmol), 2-butanone (54 mg, 0.75 mmol) and PEG3400 (60 mg) in toluene (4 mL) at 100 °C for 24h. The crude product was purified by Preparative TLC (eluted with 9% EtOAc in hexanes) to provide the desired product as a white solid (128 mg, 68%). MP = 98.5-101.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.14 (m, 3H), 3.98-3.87 (m, 4H), 2.85-2.81 (m, 2H), 2.35-2.18 (m, 2H), 2.08-1.97 (m, 1H), 1.92-1.72 (m, 4H), 1.64-1.24 (m, 6H), 0.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.4, 139.1, 131.5, 128.4, 127.1, 119.3, 119.2, 65.2, 64.5, 49.3, 46.0, 43.7, 38.5, 34.2, 30.6, 29.2, 26.7, 25.8, 22.3, 14.3. IR (thin film): 2937, 1481, 1106 cm⁻¹; Elemental analysis for C₂₀H₂₅BrO₂: C, 63.66; H, 6.68. Found: C, 63.89; H, 6.63.



(8*R*,9*S*,13*S*,14*S*)-3-chloro-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolane]:

The title compound was prepared according to the general procedure with (8*R*,9*S*,13*S*,14*S*)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolan]-3-yl trifluoromethanesulfonate

(223 mg, 0.5 mmol), potassium chloride (56 mg, 0.75 mmol), Pd₂(dba)₃ (11.5mg, 2.5 mol%), *t*-BuBrettPhos (15.2 mg, 6.25 mol%), *i*-Bu₃Al (0.75 mL, 0.75 mmol), 2-butanone (54 mg, 0.75 mmol) and PEG3400 (60 mg) in toluene (4 mL) at 100 °C for 24h. The crude product was purified by Preparative TLC (eluted with 10% EtOAc in hexanes) to provide the desired product as a white solid (108 mg, 65%). MP = 104-106 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, J = 8.4 Hz, 1H), 7.11-7.06 (m, 2H), 3.99-3.88 (m, 4H), 2.86-2.82 (m, 2H), 2.34-2.21 (m, 2H), 2.09-1.98 (m, 1H), 1.95-1.74 (m, 4H), 1.69-1.27 (m, 6H), 0.89 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 138.8, 138.7, 131.0, 128.6, 126.7, 125.5, 119.3, 65.2, 64.5, 49.3, 46.0, 43.7, 38.6, 34.1, 30.6, 29.3, 26.6, 25.9, 22.3, 14.2. IR (thin film): 2938, 2873, 1483, 1108 cm⁻¹; Elemental analysis for C₂₀H₂₅ClO₂: C, 72.17; H, 7.57. Found: C, 72.05; H, 7.72.



(8S,9S,10R,13R,14S,17R)-3-chloro-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene:¹⁴ The title compound was prepared according to the general procedure with (8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,7,8,9,10,11,12,13,14,15,16,17-

dodecahydro-1H-cyclopenta[a] phenanthren-3-yl trifluoromethanesulfonate (517 mg, 1 mmol), potassium chloride (112 mg, 1.5 mmol), Pd₂(dba)₃ (22.9mg, 2.5 mol%), *t*-BuBrettPhos (30.3 mg, 6.25 mol%), *i*-Bu₃Al (1.5 mL, 1.5 mmol), 2-butanone (108 mg, 1.5 mmol) and PEG3400 (120 mg) in toluene (8 mL) at 100 °C for 20h. The crude product was purified by flash chromatography (Biotage, eluted with hexanes) to provide the desired product as a white solid (354 mg, 88%). MP = 64-66 °C. ¹H NMR (300 MHz, CDCl₃) δ 6.06 (d, J = 2.4 Hz, 1H), 5.41-5.39 (m, 1H), 2.57-2.46 (m, 1H), 2.32 (dd, J = 17.7, 4.5 Hz, 1H), 2.21-2.11 (m, 1H), 2.03 (dt, J = 12.3, 3.6 Hz, 1H), 1.91-1.79 (m, 2H), 1.70-1.00 (m, 20H), 0.97 (s, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H), 0.71 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 140.5, 130.2, 127.0, 124.3, 56.8, 56.1, 47.9, 42.4, 39.7, 39.5, 36.2, 35.8, 34.8, 34.4, 31.8, 31.7, 30.7, 28.2, 28.0, 24.2, 23.8, 22.8, 22.6, 21.1, 18.9, 18.7, 11.9;

References:

- Lehmkuhl, H. *Liebigs Ann. Chem.* **1968**, 719, 40.
- Fors, B. P.; Dooleweerd, K.; Zeng, Q.; Buchwald, S. L. *Tetrahedron*, **2009**, 65, 6576.
- Furuya, T.; Strom, A. E.; Ritter, T. *J. Am. Chem. Soc.* **2009**, 131, 1662.
- Holt, D. A.; Levy, M. A.; Oh, H. J.; Erb, J. M.; Heaslip, J. I.; Brandt, M.; Lan-Hargest, H. Y.; Metcalf, B. W. *J. Med. Chem.* **1990**, 33, 943.
- Sengupta, S.; Leite, M.; Raslan, D.; Quesnelle, C.; Snieckus, V. *J. Org. Chem.* **1992**, 57, 4066.
- Cacchi, S.; Morera, E.; Ortar, G. *Org. Synth.* **1990**, 68, 138.
- Watson, D. A.; Su, M.; Teverovskiy, G.; Zhang, Y.; García-Fortanet, J.; Kinzel, T.; Buchwald, S. L. *Science* **2009**, 325, 1661.
- Mee, S. P. H.; Lee, V.; Baldwin, J. E. *Chem.-Eur. J.* **2005**, 11, 3294.
- Finke, A. D.; Elleby, E. C.; Boyd, M. J.; Weissman, H.; Moore, J. S. *J. Org. Chem.* **2009**, 74, 8897.
- Park, N.; Jung, Y.; Park, C.; Seong, C.; Lim, H.; *Bull. Korean Chem. Soc.* **2001**, 22, 139.
- Leonard, N. J.; Hyson, A. M.; *J. Am. Chem. Soc.* **1949**, 71, 1392.
- Percec, V.; Okita, S.; *J. Polym. Sci., Part A: Polym. Chem.* **1993**, 31, 1087.
- Johns, W. F. *J. Org. Chem.* **1961**, 26, 4583.
- Ross, J. A.; Martz, M. D. *J. Org. Chem.* **1964**, 29, 2784.

